Ken Izumori Selected Research

psicose (D-psicose)

12/2017	d-Allulose, a stereoisomer of d-fructose, extends Caenorhabditis elegans lifespan through a dietary restriction mechanism: A new candidate dietary restriction mimetic.
6/2016	A novel rare sugar inhibitor of murine herpes simplex keratitis.
2/2010	Failure of d-psicose absorbed in the small intestine to metabolize into energy and its low large intestinal fermentability in humans.
9/2009	d-Psicose Inhibits Intestinal alpha-Glucosidase and Suppresses the Glycemic Response after Ingestion of Carbohydrates in Rats.
9/2006	Effects of dietary D-psicose on diurnal variation in plasma glucose and insulin concentrations of rats.
4/2006	Improved microcirculatory effect of D-allose on hepatic ischemia reperfusion following partial hepatectomy in cirrhotic rat liver.
11/2005	Neuroprotective effect of D-psicose on 6-hydroxydopamine-induced apoptosis in rat pheochromocytoma (PC12) cells.
7/2005	Growth inhibitory effect of D-allose on human ovarian carcinoma cells in vitro.
1/2003	Metabolic effects of D-psicose in rats: studies on faecal and urinary excretion and caecal fermentation.
12/2002	Effects of oral acute administration and subchronic feeding of several levels of D-psicose in rats.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ken Izumori Research Topics

Disease

5	Body Weight (Weight, Body) 06/2013 - 02/2002
3	Hyperglycemia 12/2017 - 09/2006
3	Reperfusion Injury 04/2006 - 01/2003
2	Neoplasms (Cancer) 06/2022 - 10/2005
2	Infections 01/2020 - 06/2016
2	Ovarian Neoplasms (Ovarian Cancer) 10/2007 - 07/2005
2	Ischemia 04/2006 - 01/2004
2	Conversion Disorder (Astasia Abasia) 09/2005 - 08/2005
2	Hypertrophy 01/2003 - 12/2002
1	Urinary Bladder Neoplasms (Bladder Cancer) 06/2022
1	Hypertension (High Blood Pressure) 01/2019
1	Obesity 12/2017
1	Keratitis 06/2016
1	Herpetic Keratitis 06/2016
1	Hypersensitivity (Allergy) 11/2012
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2007
1	Weight Gain 09/2006
1	Parkinson Disease (Parkinson's Disease) 11/2005
1	Pheochromocytoma 11/2005
1	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2005
1	Carcinoma (Carcinomatosis) 07/2005
1	Weight Loss (Weight Reduction) 02/2002

Drug/Important Bio-Agent (IBA)

11	psicose (D-psicose)IBA 12/2017 - 02/2002
9	SugarsIBA 06/2022 - 02/2002
9	alloseIBA 06/2022 - 01/2003
3	FructoseIBA 12/2017 - 02/2002
2	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 02/2010
2	Sucrose (Saccharose)IBA 09/2009 - 02/2002
1	Pharmaceutical PreparationsIBA 06/2022
1	Polysaccharides (Glycans)IBA 01/2020
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019
1	Ophthalmic Solutions (Eye Drops)IBA 06/2016
1	Starch (Cornstarch)IBA 06/2013
1	High Fructose Corn SyrupIBA 06/2013
1	MaltoseIBA 09/2009
1	Culture MediaIBA 10/2007
1	EnzymesIBA 04/2006
1	Glutathione (Reduced Glutathione)IBA 11/2005
1	Oxidopamine (6 Hydroxydopamine)IBA 11/2005
1	Neuroprotective AgentsIBA 11/2005
1	Biological ProductsIBA 10/2005
1	Sorbitol (Yal)FDA Link 09/2005
1	ErythritolIBA 08/2005
1	altritolIBA 07/2005
1	D-altroseIBA 07/2005
1	Polyethylene (Polythene)IBA 01/2004
1	Superoxide DismutaseIBA 01/2004
1	Saline SolutionIBA 01/2004
1	Allopurinol (Remid)FDA LinkGeneric 01/2004
1	Volatile Fatty AcidsIBA 01/2003
1	Sweetening Agents (Sweeteners)IBA 02/2002

Therapy/Procedure

1	Oral Administration 06/2022
1	Hepatectomy 04/2006
1	Catheters 01/2004
1	Transplantation 01/2003